Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aidan Power

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Journal of Clinical Pharmacology|March 24, 2006
Race and ethnicity in the era of emerging pharmacogenomicsLea Harty, Keith Johnson, Aidan Power
Current Topics in Medicinal Chemistry|September 27, 2005
Pharmacogenomics: integration into drug discovery and developmentKeith Johnson, John Thompson, Aidan Power
International Journal of Molecular Sciences|July 2, 2021
Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease ProgressionMartin Tolar, John Hey, Aidan Power, et al.
Plos One|October 27, 2022
Medical student wellness assessment beyond anxiety and depression: A scoping reviewKay-Anne Haykal, Lara Pereira, Aidan Power, et al.
International Journal of Molecular Sciences|March 13, 2024
The Single Toxin Origin of Alzheimer's Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and PreventionMartin Tolar, John A Hey, Aidan Power, et al.
The Journal of Clinical Psychiatry|June 29, 2002
A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophreniaSteven R Hirsch, Werner Kissling, Josef Bäuml, et al.
Pharmacogenomics|December 24, 2008
Developing the evidence base for applying pharmacogenomics: proceeds from DIA Workshop IV--Breakout Session 1Martin Armstrong, Christina Bromley, Nadine Cohen, et al.
Pharmacogenomics|December 15, 2010
Designing pharmacogenomic studies to be fit for purposeDaniel K Burns, Arlene R Hughes, Aidan Power, et al.
Drugs|June 20, 2024
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer's Disease Using Quantitative Systems Pharmacology ModelJohn A Hey, Jeremy Y Yu, Susan Abushakra, et al.
CNS Drugs|November 14, 2018
Correction to: Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human BrainJohn A Hey, Petr Kocis, Jakub Hort, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Journal of Clinical Pharmacology|March 24, 2006
Race and ethnicity in the era of emerging pharmacogenomicsLea Harty, Keith Johnson, Aidan Power
Current Topics in Medicinal Chemistry|September 27, 2005
Pharmacogenomics: integration into drug discovery and developmentKeith Johnson, John Thompson, Aidan Power
International Journal of Molecular Sciences|July 2, 2021
Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease ProgressionMartin Tolar, John Hey, Aidan Power, et al.
Plos One|October 27, 2022
Medical student wellness assessment beyond anxiety and depression: A scoping reviewKay-Anne Haykal, Lara Pereira, Aidan Power, et al.
International Journal of Molecular Sciences|March 13, 2024
The Single Toxin Origin of Alzheimer's Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and PreventionMartin Tolar, John A Hey, Aidan Power, et al.
The Journal of Clinical Psychiatry|June 29, 2002
A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophreniaSteven R Hirsch, Werner Kissling, Josef Bäuml, et al.
Pharmacogenomics|December 24, 2008
Developing the evidence base for applying pharmacogenomics: proceeds from DIA Workshop IV--Breakout Session 1Martin Armstrong, Christina Bromley, Nadine Cohen, et al.
Pharmacogenomics|December 15, 2010
Designing pharmacogenomic studies to be fit for purposeDaniel K Burns, Arlene R Hughes, Aidan Power, et al.
Drugs|June 20, 2024
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer's Disease Using Quantitative Systems Pharmacology ModelJohn A Hey, Jeremy Y Yu, Susan Abushakra, et al.
CNS Drugs|November 14, 2018
Correction to: Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human BrainJohn A Hey, Petr Kocis, Jakub Hort, et al.
Pageof 2